Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

PHASE4CompletedINTERVENTIONAL

Enrollment

1,600

Participants

Timeline

Start Date

November 3, 2017

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions

InfluenzaFlu

Interventions

BIOLOGICAL

SP Shz TIV

0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0

BIOLOGICAL

Hualan TIV

0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0

Trial Locations (1)

Sanofi Pasteur Investigational Site 001, Huai'an